ArticleInternational journal of pharmaceutics: X2025
Fucoidan/Polyvinylpyrrolidone/Hesperitin nanoparticle complex for corneal injury treatment: Synthesis, characterization, and therapeutic efficacy.
Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corneal injury is a common ailment that, if not addressed promptly and efficiently, has the potential to result in significant visual impairment. This study investigates the therapeutic potential of a novel FU/PVP/Hes nanoparticle complex composed of fucoidan (FU), polyvinylpyrrolidone (PVP), and hesperitin (Hes) for corneal injury treatment. The FU/PVP/Hes nanoparticles were synthesized using a solvent evaporation method and characterized for their morphology, size distribution, biocompatibility, antioxidant activity, and anti-inflammatory capacity. The nanoparticles demonstrated excellent biocompatibility with low hemolysis rates and minimal cytotoxicity. They also exhibited potent antioxidant and anti-inflammatory properties, which were attributed to the enhanced solubility and bioavailability of Hes through nanoparticle formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.